2016/17 Full Year Results, page-47

I surely agree that 100m EBITDA and 70-80m NPAT is likely. I hope the we start seeing a more positive outlook from here.
I note that we have almost completed year 2 of a 3-5 year turnaround plan and the heavy lifting has already been done.
From here I will continue to hold past $2 to see how much potential the company really has and enjoy the dividends.
I would speculate that within the next 12-18 months Crescent will be extolling the virtues of the company with a view to selling it at 15-20x NPAT or $2.5 to $3.